TG Therapeutics, Inc.
TGTX
$40.11
+9.47%
TG Therapeutics, Inc. is a commercial-stage biotechnology company focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. Its primary commercial asset is BRIUMVI (ublituximab-xiiy), an FDA-approved therapy for relapsing forms of multiple sclerosis (RMS), and it maintains a pipeline including UBLITUXIMAB, SUB-Q UBLITUXIMAB, and AZER-CEL. The company is establishing itself as a commercial entity in the competitive MS market, leveraging its integrated platform to drive sales growth. The current investor narrative centers on the successful commercial launch and market penetration of BRIUMVI, with recent quarterly revenue of $192.6 million demonstrating a significant ramp, alongside ongoing pipeline development and international expansion efforts.…
TGTX
TG Therapeutics, Inc.
$40.11
Investment Opinion: Should I buy TGTX Today?
Rating: Hold. The core thesis is that TGTX presents a compelling but high-risk story of a successful drug launch at a reasonable valuation, yet the extreme concentration risk and lack of cash flow conversion warrant caution until greater visibility on sustained growth emerges.
Supporting evidence includes a trailing P/E of 9.62x that is low for a profitable biotech with 78% YoY revenue growth, a strong operating margin of 20.01%, and a solid balance sheet with a debt-to-equity of 0.40. Analyst expectations for forward EPS of $4.28, if achieved, would imply significant earnings growth from the current level. However, the negative free cash flow and high beta of 1.682 temper the optimism.
The two biggest risks are a deceleration in BRIUMVI's revenue growth below the implied run-rate from the $2.35B analyst estimate, and a failure to generate sustained positive operating cash flow. This Hold would upgrade to a Buy if the company demonstrates consecutive quarters of positive free cash flow and maintains quarterly revenue growth above 20% sequentially. It would downgrade to a Sell if revenue growth stalls or turns negative. Relative to its own compressed valuation history, the stock appears fairly valued, but it carries a premium to its current earnings based on future expectations.
Sign up to view all
TGTX 12-Month Price Forecast
TGTX is a classic 'show me' story. The explosive launch data and path to profitability are undeniable positives, justifying a valuation well above pre-revenue levels. However, the investment is binary on BRIUMVI's continued success, and the market is rightly skeptical until cash flow turns sustainably positive and the pipeline demonstrates value. The neutral stance reflects this balance: the current price fairly reflects the proven growth but also the substantial risks. The stance would upgrade to bullish on evidence of sustained >20% sequential revenue growth and positive quarterly FCF. It would turn bearish on any quarter showing revenue deceleration or a significant cash burn increase.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on TG Therapeutics, Inc.'s 12-month outlook, with a consensus price target around $52.14 and implied upside of +30.0% versus the current price.
Average Target
$52.14
2 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
2
covering this stock
Price Range
$32 - $52
Analyst target range
Analyst coverage for TGTX is limited, with only two firms providing estimates, indicating this is a stock with lower institutional following typical of small to mid-cap biotechs. The consensus sentiment, based on recent institutional ratings, appears cautiously optimistic with a mix of 'Buy' and 'Neutral' or 'Overweight' stances; for example, JP Morgan maintains an 'Overweight' rating while Goldman Sachs has a 'Neutral'. The average revenue estimate for the forward period is $2.35 billion, with a range from $2.18 billion to $2.53 billion, and the average EPS estimate is $4.28. The wide target range for both revenue and EPS signals high uncertainty among the few covering analysts, likely stemming from the unpredictability of drug launch trajectories, competitive dynamics in the MS market, and pipeline developments. The lack of a published consensus price target in the data, combined with minimal analyst count, suggests higher volatility and less efficient price discovery, requiring investors to conduct more independent fundamental analysis.
Bulls vs Bears: TGTX Investment Factors
The bull case is anchored in TGTX's demonstrable commercial success, with explosive 78% YoY revenue growth and a transition to profitability at attractive valuation multiples. The bear case highlights the extreme concentration risk in a single drug, negative free cash flow, and the stock's high volatility. Currently, the bull side has stronger evidence due to the concrete, accelerating financial results. However, the single most important tension in the investment debate is whether BRIUMVI's launch momentum can be sustained to justify the high forward growth expectations priced into the stock, or if growth will decelerate, exposing the company's lack of pipeline diversification and leading to further multiple compression.
Bullish
- Explosive Revenue Growth: Q4 2025 revenue of $192.6 million grew 78% year-over-year, driven by the successful launch of BRIUMVI. Sequential quarterly growth from $120.9M to $192.6M throughout 2025 demonstrates strong commercial execution and market uptake.
- Attractive Valuation on Earnings: The stock trades at a trailing P/E of 9.62x, which is near the bottom of its recent historical range (from 285.7x in Q1 2025). This low multiple, combined with a forward P/E of 14.25x, suggests the market may be undervaluing the company's transition to profitability.
- Strong Profitability Metrics: The company achieved a net income of $23.0 million in Q4 2025 and boasts a robust gross margin of 80.16%. The trailing twelve-month operating margin of 20.01% indicates sustainable core profitability from its commercial operations.
- Solid Balance Sheet & Liquidity: A current ratio of 4.10 and a debt-to-equity ratio of 0.40 provide a strong financial foundation with ample liquidity and manageable leverage. This supports continued commercial investment and pipeline development.
Bearish
- Extreme Revenue & Valuation Concentration: The investment thesis is entirely dependent on BRIUMVI, which generated $189.1M of the $192.6M total Q4 revenue. Any slowdown in its launch, competitive pressure, or safety issue would have an immediate and severe impact on the stock.
- Negative Free Cash Flow: Despite profitability, the company's trailing twelve-month free cash flow is negative $24.99 million. This indicates that earnings are not yet fully converting to cash, raising questions about the sustainability of its growth model without further capital.
- High Volatility & Market Underperformance: With a beta of 1.682, the stock is 68% more volatile than the market. It has underperformed the SPY by 14.36% over the past year (+13.52% vs. +27.88%), indicating higher risk without commensurate recent reward.
- Limited Analyst Coverage & High Uncertainty: Only two analysts provide estimates, leading to less efficient price discovery. The wide revenue estimate range ($2.18B to $2.53B) and lack of a consensus price target reflect high uncertainty about the commercial trajectory.
TGTX Technical Analysis
The stock is in a strong uptrend over the past year, evidenced by a 1-year price change of +13.52%, although it has significantly underperformed the broader market (SPY +27.88%). As of the latest close at $38.87, the price is trading at approximately 43% of its 52-week range ($25.28 to $44.65), indicating it has retreated meaningfully from its recent highs and is positioned in the lower-middle portion of its annual band, suggesting a potential consolidation or pullback phase after a strong run. Recent momentum has been volatile but positive; the stock gained 31.63% over the last three months, significantly outpacing the SPY's 8.15% gain, yet the 1-month gain is a more modest +1.46%, which lags the market's 4.84% return, signaling a potential short-term deceleration or consolidation. The price action shows a sharp rally from early May 2026 (from ~$33.78 to a peak near $43.14) followed by a pullback, indicating profit-taking near resistance. Key technical levels are clearly defined with major support at the 52-week low of $25.28 and resistance at the 52-week high of $44.65; a decisive breakout above $44.65 would signal a resumption of the primary uptrend, while a break below the $25.28 support would be a bearish structural breakdown. The stock's beta of 1.682 indicates it is approximately 68% more volatile than the SPY, which is typical for a commercial-stage biotech and necessitates larger position sizing adjustments for risk management.
Beta
1.68
1.68x market volatility
Max Drawdown
-42.0%
Largest decline past year
52-Week Range
$25-$45
Price range past year
Annual Return
+10.2%
Cumulative gain past year
| Period | TGTX Return | S&P 500 |
|---|---|---|
| 1m | +12.3% | +5.0% |
| 3m | +38.2% | +10.7% |
| 6m | +30.4% | +10.0% |
| 1y | +10.2% | +26.5% |
| ytd | +37.0% | +10.6% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
TGTX Fundamental Analysis
Revenue growth has been explosive, with the most recent quarterly revenue (Q4 2025) reaching $192.6 million, representing a 78% year-over-year increase from $108.2 million in Q4 2024. This growth is primarily driven by the successful commercial launch of BRIUMVI, with product revenue constituting the vast majority ($189.1 million) of the total. The trajectory shows sequential quarterly revenue growth from $120.9M (Q1 2025) to $192.6M (Q4 2025), indicating strong commercial execution and market uptake. The company has achieved profitability with a net income of $23.0 million in Q4 2025, a significant improvement from a net loss of $10.7 million in Q1 2024. Gross margins are robust at 80.16% for the quarter, and the trailing twelve-month net margin stands at a healthy 72.56%, though this is inflated by a one-time tax benefit in Q3 2025; the operating margin of 20.01% provides a more normalized view of core profitability. The balance sheet and cash flow picture is mixed: the company has a strong current ratio of 4.10 and a manageable debt-to-equity ratio of 0.40, indicating solid liquidity and moderate leverage. However, the trailing twelve-month free cash flow is negative at -$24.99 million, and quarterly operating cash flow has been volatile, turning positive at $19.66 million in Q4 2025 after being negative in prior 2025 quarters. The high Return on Equity (ROE) of 69.0% is impressive but is influenced by a relatively small equity base and the aforementioned tax benefit.
Quarterly Revenue
$192574000.0B
2025-12
Revenue YoY Growth
+0.78%
YoY Comparison
Gross Margin
+0.80%
Latest Quarter
Free Cash Flow
$-24986000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is TGTX Overvalued?
Given the company's positive net income, the primary valuation metric is the Price-to-Earnings (P/E) ratio. The trailing P/E ratio is 9.62x, while the forward P/E is 14.25x based on estimated EPS. The higher forward multiple suggests the market is pricing in expectations for future earnings growth, though the modest premium also implies some normalization from the unusually high trailing net margin. Compared to the broader biotechnology industry, which often trades at elevated P/E multiples due to growth expectations, TG Therapeutics' trailing P/E of 9.6x appears relatively low, potentially reflecting skepticism about the sustainability of its current profitability or concerns about future competition. Historically, the stock's own valuation has compressed dramatically; for instance, its trailing P/E ratio was 46.25x as of Q4 2025 and has ranged as high as 285.7x in Q1 2025. The current P/E of 9.6x is near the bottom of its recent historical range, which could signal either a compelling value opportunity if fundamentals are improving or a market re-rating due to perceived peak growth for its lead asset.
PE
9.6x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range -50x~286x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
33.4x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks center on the company's complete dependence on a single commercial asset, BRIUMVI, which constituted 98% of Q4 2025 revenue. While gross margins are robust at 80.16%, the negative trailing twelve-month free cash flow of -$24.99 million indicates the business is still cash-consumptive despite reporting net income, potentially requiring additional funding if this trend persists. The high Return on Equity of 69.0% is impressive but is inflated by a small equity base and a one-time tax benefit, masking underlying operational leverage.
Market & Competitive Risks are pronounced. The stock trades at a forward P/E of 14.25x, which, while not extreme for biotech, represents a significant premium to its own trailing P/E of 9.62x, implying high growth expectations that are vulnerable to compression. The competitive Multiple Sclerosis market is crowded with entrenched players, and any loss of market share or pricing pressure for BRIUMVI would directly impact the top line. The stock's beta of 1.682 confirms its high sensitivity to market swings and sector sentiment, making it prone to sharp drawdowns in risk-off environments.
The Worst-Case Scenario involves BRIUMVI failing to meet lofty growth expectations due to intensified competition, slower-than-expected market penetration, or an adverse safety event. This could trigger analyst downgrades, a collapse in the forward earnings multiple, and a flight of capital. A realistic downside could see the stock re-testing its 52-week low of $25.28, which represents a potential loss of approximately -35% from the current price of $38.87. The historical max drawdown of -42.01% provides a precedent for such severe corrections.
FAQ
The key risks are, in order of severity: 1) Product Concentration Risk: Over 98% of revenue comes from BRIUMVI, making the company vulnerable to any launch setback. 2) Financial Sustainability Risk: Despite net income, trailing free cash flow is negative (-$24.99M), indicating the business model is not yet self-funding. 3) Competitive & Market Risk: The MS market is fiercely competitive, and the stock's high beta of 1.682 makes it prone to sharp declines in weak markets. 4) Execution & Coverage Risk: With only two covering analysts, there is less institutional support and higher uncertainty around forecasts.
Our 12-month outlook presents three scenarios. The Base Case (50% probability) sees the stock trading between $38 and $44, as BRIUMVI growth moderates but meets current analyst expectations. The Bull Case (30% probability) targets $44.65 to $52+ on outperformance and pipeline news. The Bear Case (20% probability) warns of a drop to the $25-$32 range if growth disappoints. The Base Case is most likely, hinging on the assumption that quarterly revenue stabilizes above $200M without major setbacks. The average analyst EPS forecast of $4.28 supports the base-to-bull scenarios.
TGTX appears fairly valued relative to its current earnings but carries a growth premium. The trailing P/E of 9.62x is low compared to many biotechs and is at the bottom of its own historical range, suggesting undervaluation on a static basis. However, the forward P/E of 14.25x implies the market is paying for future growth. The valuation is reasonable if the company hits its $2.35B revenue target, but it is vulnerable if growth decelerates. The market is pricing in successful execution, leaving little room for error.
TGTX is a speculative buy for risk-tolerant investors who believe in the continued blockbuster potential of BRIUMVI. The 78% YoY revenue growth and low trailing P/E of 9.6x are compelling, and analyst EPS estimates of $4.28 suggest significant upside if executed. However, it is not a good buy for conservative portfolios due to its single-product dependence, negative free cash flow, and high volatility (beta 1.682). The investment carries a realistic downside risk of -35% to its 52-week low if the launch stumbles.
TGTX is primarily suitable for a medium- to long-term investment horizon of 2-3 years, allowing time for the BRIUMVI launch to mature, cash flow to turn positive, and pipeline value to be clarified. Its high volatility and beta make it a poor candidate for short-term trading unless based on specific catalyst timing (e.g., earnings). The company pays no dividend, eliminating an income rationale. Given the binary nature of biotech commercialization, investors should be prepared for significant price swings and have a minimum holding period that allows the fundamental story to play out.